According to a new study, giving probiotics to babies while they are being weaned may reduce their chances of developing allergic conditions such as eczema. Although further research is required, probiotics may have a significant role to play in several conditions caused by allergic inflammation. This represents both a threat and an opportunity to pharma companies.
Ark Therapeutics has announced that its novel gene-based targeting technology Scavidin can halt tumor progression while preventing chemotherapy side effects. Although clinical trials are urgently required to confirm Scavidin's efficacy, this leading edge technology could spell the end for unpleasant toxicities associated with chemotherapy and radiation, particularly for elderly patients.
Edit my basket
© Datamonitor 2014. All rights reserved
Terms & Conditions